Johnson & Johnson has submitted its first marketing application for nipocalimab, seeking approval for the FcRn blocker in generalised myasthenia gravis (gMG), where it would compete with rivals in ...

The EMA’s human medicines committee issued a positive opinion on Rystiggo (rozanolixizumab) as an add-on to standard therapy for the treatment of adult gMG patients who are anti-acetylcholine ...

anti-LRP4+) adults with generalised myasthenia gravis (gMG). 1, 2 Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL b and QMG c scores over 84 ...

With the highest MG-ADL response rate among all drugs for gMG with phase 3 studies reported to date, Telitacicept will provide an important new treatment option gMG. Telitacicept is a novel ...

Brisbane, Queensland, Australia--(Newsfile Corp. - March 20, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to announce that it has completed its previously ...